Dr. Peter R. Graze, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1971)
- Years since graduation
- 55
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 528
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1971Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D0016364
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Luminis Health Anne Arundel Medical Center, Inc Annapolis, MD
Medical groups
- Maryland Oncology Hematology PA (104 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 528
- Services billed
- 119,576
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 15,000 | 18 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11,880 | 14 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 10,710 | 11 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 10,460 | 16 |
| Injection, aprepitant, 1 mg | 4,550 | 21 |
| Injection, denosumab, 1 mg | 2,160 | 13 |
| Injection, ferric derisomaltose, 10 mg | 2,000 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,160 | 52 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,020 | 251 |
| Established patient office or other outpatient visit, 30-39 minutes | 542 | 217 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 45 |
| Hydroxyurea Other prescribers in Annapolis, MD | 38 |
| Allopurinol Other prescribers in Annapolis, MD | 36 |
| Jakafi (ruxolitinib phosphate) | 35 |
| Dexamethasone Other prescribers in Annapolis, MD | 28 |
| Ondansetron Hcl Other prescribers in Annapolis, MD | 27 |
| Xarelto (rivaroxaban) Other prescribers in Annapolis, MD | 25 |
| Eliquis (apixaban) Other prescribers in Annapolis, MD | 25 |
| Levothyroxine Sodium Other prescribers in Annapolis, MD | 24 |
| Olanzapine Other prescribers in Annapolis, MD | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 49 payments worth $1,236 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $165 |
|---|---|
| AbbVie Inc. | $151 |
| Janssen Biotech, Inc. | $99.35 |
| Pfizer Inc. | $94.75 |
| AstraZeneca Pharmaceuticals LP | $84.40 |
| Daiichi Sankyo Inc. | $59.34 |
| Astellas Pharma US Inc | $53.49 |
| Regeneron Healthcare Solutions, Inc. | $51.37 |
| Food and Beverage | $1,236 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.